Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative

1. A method for the treatment of thromboembolic disorders which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I):

in which:

the wavy line denotes a bond situated either below or above the plane of the pyranose ring,

the formula (Po):

denotes a polysaccharide, comprising n identical or different monosaccharide units, bonded via its anomeric carbon to Pe, in which the formula:

represents a monosaccharide unit with a pyranose structure chosen from hexoses, pentoses and the corresponding deoxy sugars, this unit being bonded via its anomeric carbon to another monosaccharide unit and the hydroxyl groups of this unit being substituted by identical or different R 1 groups,

Pe represents a pentasaccharide of structure:

h is 1 or 2,

n is an integer from 0 to 25,

R 1 represents the -T-Biot linkage, a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 2 represents the -T-Biot linkage, a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 3 represents the -T-Biot linkage or a (C 1 -C 6 )alkoxy group,

R 4 represents the -T-Biot linkage, a (C 1 -C 6 )alkoxy group or an —OSO 3 − group, or else R 4 constitutes an —O—CH 2 —bridge, the —CH 2 —group being bonded to the carbon atom carrying the carboxyl functional group on the same ring;

at least one of the R 1 , R 2 , R 3 or R 4 substituents represents a -T-Biot group,

W represents an oxygen atom or a methylene group,

T represents one of the linkages chosen from:

NH,

in which j and k are identical or different integers from 1 to 10;

Biot represents the group:

or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 , wherein said compound has the formula (I.2):

in which:

T is chosen from:

NH,

in which j and k are identical or different integers from 1 to 10;

Biot represents the group:

Pe represents a pentasaccharide of structure:

in which:

R 1 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 2 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 3 represents a (C 1 -C 6 )alkoxy group,

R 4 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group, or else R 4 constitutes an —O—CH 2 —bridge, the —CH 2 group being bonded to the carbon atom carrying the carboxyl functional group on the same ring,

W represents an oxygen atom or a methylene group, or

a pharmaceutically acceptable salt thereof.

3. A method according to claim 1 , wherein said compound has the formula (I.3):

wherein

R 1 represents the -T-Biot linkage, a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 2 represents the -T-Biot linkage, a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 3 represents the -T-Biot linkage or a (C 1 -C 6 )alkoxy group,

R 4 represents the -T-Biot linkage, a (C 1 -C 6 )alkoxy group or an —OSO 3 ‘ group, or else R 4 constitutes an —O—CH 2 —bridge, the —CH 2 —group being bonded to the carbon atom carrying the carboxyl functional group on the same ring;

at least one of the R 1 , R 2 , R 3 or R 4 substituents represents a -T-Biot group,

W represents an oxygen atom or a methylene group,

T represents one of the linkages chosen from:

NH,

in which j and k are identical or different integers from 1 to 10;

Biot represents the group:

or a pharmaceutically acceptable salt thereof.

4. A method according to claim 1 , wherein said compound has the formula (I.4):

in which:

T is chosen from:

NH,

in which j and k are identical or different integers from 1 to 10;

Biot represents the group:

R 1 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 2 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group,

R 3 represents a (C 1 -C 6 )alkoxy group,

R 4 represents a (C 1 -C 6 )alkoxy group or an —OSO 3 − group, or else R 4 constitutes an —O—CH 2 —bridge, the —CH 2 —group being bonded to the carbon atom carrying the carboxyl functional group on the same ring,

W represents an oxygen atom or a methylene group, or

a pharmaceutically acceptable salt thereof.

5. A method according to claim 1 , wherein said compound is chosen from:

Methyl (2,3 ,4,6-tetra-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3 ,6-tri-O-sulphonato -α-D-glucopyranosyl)-(1→4)-(2,3 ,6-tri-O-sulphonato-β-D-glucopyranosyl)-(1→4)-(6-biotinamido-6-deoxy-2,3-di-O-methyl-α-D-glucopyranosyl)-(1→4)-(2,3 ,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)- [(2,3 ,6-tri-O-methyl-α-D-glucopyranosyl)-(1→4)-O-(2,3 ,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)] 3 -(6-O-sulphonato-2,3 -di-O-methyl-α-D -glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3 ,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt,

Methyl (2,3 ,4,6-tetra-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3 ,6-tri-O-sulphonato -α-D-glucopyranosyl)-(1→4)-(2,3 ,6-tri-O-sulphonato-β-D-glucopyranosyl)-(1→4)-(6- [6-(biotinamido)hexamido]-6-deoxy-2,3 -di-O-methyl-α-D-glucopyrano syl)-(1→4)-(2,3 ,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)-[(2,3 ,6-tri-O-methyl-α-D-glucopyranosyl) -(1→4)-O-(2,3 ,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)] 3 -(6-O-sulphonato-2,3 -di-O -methyl-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid) -(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L -idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt,

Methyl (2,3,4,6-tetra-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-sulphonato -α-D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-sulphonato-β-D-glucopyranosyl)-(1→4)-(6-[6-(6-biotanamido-hexamido)hexamido]-6-deoxy-2,3-di-O-methyl-α-D-glucopyranosyl) -(1→4)-(2,3,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)-[(2,3,6-tri-O-methyl-α-D -glucopyranosyl)-(1→4)-O-(2,3,6-tri-O-methyl-β-D-glucopyranosyl)-(1→4)] 3 -(6-O -sulphonato-2,3-di-O-methyl-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D -glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4) -(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt,

Methyl (2-biotinamido-2-deoxy-3,4-di-O-methyl-6-O-sulphonato-α-D-glucopyranosyl) -(1→4)-(2,3-di-O-methyl-(3-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O -sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt,

Methyl (2-[N-(6-biotinamidohexanoyl)]-2-deoxy-3,4-di-O-methyl-6-O-sulphonato-α-D -glucopyranosyl)-(1→4)-(2,3-di-O-methyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L-idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt, and

Methyl (2-[6-(6-biotinamidohexamido)hexamido]-2-deoxy-3,4-di-O-methyl-6-O -sulphonato-α-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-(3-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-sulphonato-a-D-glucopyranosyl)-(1→4)-(2,3-di-O-methyl-α-L -idopyranosyluronic acid)-(1→4)-2,3,6-tri-O-sulphonato-α-D-glucopyranoside, sodium salt.

6. The method of claim 1 wherein said thromboembolic disorders are thromboembolic pathologies of venous origin.

7. The method of claim 6 wherein said thromboembolic pathologies are pulmonary embolisms.